Table 2.
Patient demographics and clinical characteristics at diagnosis as reported by physicians
| Patients, N = 491 | |
|---|---|
| Mean (SD) age at diagnosis, years | 65.4 (11.8) |
| Sex, n (%) | |
| Male | 269 (54.8) |
| Race, n (%) | |
| White | 320 (65.2) |
| Black/African American | 104 (21.2) |
| Asian | 50 (10.2) |
| American Indian or Alaska Native | 6 (1.2) |
| Native Hawaiian/Pacific Islander | 5 (1.0) |
| Other | 6 (1.2) |
| Geographic region of treating physician practice, n (%) | |
| South | 16 (35.6) |
| West | 12 (26.7) |
| Northeast | 9 (20.0) |
| Midwest | 8 (17.8) |
| Type of MF, n (%) | |
| Primary MF | 340 (69.2) |
| Post-PV MF | 87 (17.7) |
| Post-ET MF | 64 (13.0) |
| Median (IQR) disease duration at the time of the study, months | 27.3 (19.1–40.2) |
| Palpable spleen, n (%) | |
| Yes | 374 (76.2) |
| No | 116 (23.6) |
| Unknown | 1 (0.2) |
| Spleen length, n (%) | |
| < 5 cm, spleen not palpable or barely palpable | 76 (15.5) |
| ≥ 5 cm but < 10 cm; spleen palpable below the coastal margin | 152 (31.0) |
| ≥ 10 to < 20 cm; spleen palpable between the coastal margin and the umbilicus | 113 (23.0) |
| ≥ 20 cm; spleen palpable near to the umbilicus or severe splenomegaly | 32 (6.5) |
| Unknown | 1 (0.2) |
| Transfusion dependent, n (%) | |
| Yes | 124 (25.3) |
| No | 366 (74.5) |
| Unknown | 1 (0.2) |
| Symptomatic disease at diagnosis, n (%) | 312 (63.5) |
| Lab values, n (%) | |
| Blood blast > 1% | 299 (61.2) |
| Hemoglobin < 10 g/dL | 291 (59.3) |
| WBC count > 25 × 109/L | 84 (17.1) |
| Platelets < 100 × 109/L | 161 (32.8) |
ET essential thrombocythemia, IQR interquartile range, MF myelofibrosis, PV polycythemia vera, WBC white blood cell